Quarterly Result26 Oct 2026, 06:41 pm
Venus Remedies Declares Unaudited Q2 FY27 Results
AI Summary
Venus Remedies Limited announced the outcome of its Board Meeting held on October 26, 2026. The board considered and approved the unaudited financial results (Standalone and Consolidated) for the period ended September 30, 2026 (Q2 FY27). A Limited Review report was also approved and enclosed with the results. The meeting commenced at 02:45 PM and concluded at 06:00 PM. The company also highlighted an emphasis of matter regarding outstanding share application money of INR 2,859.72 Lakhs in its wholly-owned subsidiary, Venus Pharma GmbH, pending allotment.
Key Highlights
- Board approved unaudited financial results for Q2 FY27.
- Results were declared on a standalone and consolidated basis.
- A Limited Review report was approved by the Board.
- Outstanding share application money of INR 2,859.72 Lakhs noted.
- The subsidiary, Venus Pharma GmbH, is facing financial challenges.
Price Impact
More from VENUSREM